Trial Profile
An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs PVS 10200 (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Acronyms TRIUMPH
- Sponsors Shire
- 08 May 2014 New trial record